You just read:

New Biomarker Data To Be Presented at AACR Helps Predict Overall Survival in Patients with Acute Myeloid Leukemia (AML) Treated with Ceplene® and Low-dose IL-2 Immunotherapy, Including Those Over 60 Years of Age

News provided by

Immune Pharmaceuticals Inc.

19 Apr, 2016, 07:30 ET